PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
PROCEPT BioRobotics (Nasdaq: PRCT) announced an upcoming investor event scheduled for April 25, 2025, from 8:00am to 9:30am PT at the Aria Resort in Las Vegas during the American Urological Association Annual Meeting.
The event will feature presentations from the company's leadership team, including CEO Reza Zadno, CFO Kevin Waters, CCO Sham Shiblaq, and CTO Barry Templin. Clinical perspectives will be provided by distinguished physicians: Dr. Inderbir Gill from USC Urology, Dr. Brian Helfand from Endeavor Health, and Dr. Gerald Park from Kansas City Urology Care.
The event will be accessible via live webcast on the company's investor relations website, with recordings available for at least 90 days afterward.
PROCEPT BioRobotics (Nasdaq: PRCT) ha annunciato un evento per investitori programmato per il 25 aprile 2025, dalle 8:00 alle 9:30 PT, presso l'Aria Resort di Las Vegas, in occasione dell'Annual Meeting dell'American Urological Association.
L'evento presenterà interventi del team dirigenziale dell'azienda, inclusi il CEO Reza Zadno, il CFO Kevin Waters, il CCO Sham Shiblaq e il CTO Barry Templin. Le prospettive cliniche saranno fornite da medici di spicco: il Dr. Inderbir Gill della USC Urology, il Dr. Brian Helfand di Endeavor Health e il Dr. Gerald Park del Kansas City Urology Care.
L'evento sarà accessibile tramite webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, con registrazioni disponibili per almeno 90 giorni dopo.
PROCEPT BioRobotics (Nasdaq: PRCT) anunció un próximo evento para inversores programado para el 25 de abril de 2025, de 8:00 a 9:30 PT en el Aria Resort de Las Vegas durante la Reunión Anual de la Asociación Americana de Urología.
El evento contará con presentaciones del equipo de liderazgo de la empresa, incluyendo al CEO Reza Zadno, al CFO Kevin Waters, al CCO Sham Shiblaq y al CTO Barry Templin. Perspectivas clínicas serán proporcionadas por médicos distinguidos: el Dr. Inderbir Gill de USC Urology, el Dr. Brian Helfand de Endeavor Health y el Dr. Gerald Park de Kansas City Urology Care.
El evento será accesible a través de una transmisión en vivo en el sitio web de relaciones con inversores de la empresa, con grabaciones disponibles durante al menos 90 días después.
PROCEPT BioRobotics (Nasdaq: PRCT)는 2025년 4월 25일 오전 8시부터 9시 30분 PT까지 라스베이거스의 아리아 리조트에서 미국 비뇨기과 학회 연례 회의 중에 예정된 투자자 이벤트를 발표했습니다.
이 이벤트에서는 CEO Reza Zadno, CFO Kevin Waters, CCO Sham Shiblaq 및 CTO Barry Templin을 포함한 회사의 리더십 팀이 발표를 진행합니다. 임상 관점은 USC 비뇨기과의 Inderbir Gill 박사, Endeavor Health의 Brian Helfand 박사, Kansas City Urology Care의 Gerald Park 박사와 같은 저명한 의사들이 제공합니다.
이 이벤트는 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 접근 가능하며, 이후 최소 90일 동안 녹화본이 제공됩니다.
PROCEPT BioRobotics (Nasdaq: PRCT) a annoncé un prochain événement pour investisseurs prévu le 25 avril 2025, de 8h00 à 9h30 PT au Aria Resort de Las Vegas lors de la Réunion Annuelle de l'Association Américaine d'Urologie.
L'événement comportera des présentations de l'équipe de direction de l'entreprise, y compris le PDG Reza Zadno, le CFO Kevin Waters, le CCO Sham Shiblaq et le CTO Barry Templin. Des perspectives cliniques seront fournies par des médecins distingués : le Dr Inderbir Gill de USC Urology, le Dr Brian Helfand d'Endeavor Health et le Dr Gerald Park de Kansas City Urology Care.
L'événement sera accessible par webcast en direct sur le site web des relations avec les investisseurs de l'entreprise, avec des enregistrements disponibles pendant au moins 90 jours après.
PROCEPT BioRobotics (Nasdaq: PRCT) kündigte eine bevorstehende Investorenveranstaltung an, die für den 25. April 2025, von 8:00 bis 9:30 Uhr PT im Aria Resort in Las Vegas während des Jahreskongresses der American Urological Association geplant ist.
Die Veranstaltung wird Präsentationen des Führungsteams des Unternehmens umfassen, darunter CEO Reza Zadno, CFO Kevin Waters, CCO Sham Shiblaq und CTO Barry Templin. Klinische Perspektiven werden von angesehenen Ärzten bereitgestellt: Dr. Inderbir Gill von USC Urology, Dr. Brian Helfand von Endeavor Health und Dr. Gerald Park von Kansas City Urology Care.
Die Veranstaltung wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit Aufzeichnungen, die mindestens 90 Tage lang verfügbar sind.
- None.
- None.
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot.
Members of PROCEPT BioRobotics’ management team presenting include:
- Reza Zadno – Chief Executive Officer
- Kevin Waters – Chief Financial Officer
- Sham Shiblaq – Chief Commercial Officer
- Barry Templin – Chief Technology Officer
Clinical perspectives will also be provided by the following physicians:
- Dr. Inderbir Gill - Founding Executive Director for USC Urology, Chairman of Urological Cancer Surgery at Keck School of Medicine of USC
- Dr. Brian Helfand - Division Chief of Urology, Endeavor Health, Associate Chief Scientific Officer at Endeavor Health, Clinical Professor at University of Chicago, Ronald Chez Family and Richard Melman Family Endowed Chairman
- Dr. Gerald Park - Partner, Kansas City Urology Care
A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/. The webcast will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
FAQ
When and where is PROCEPT BioRobotics (PRCT) hosting its 2025 investor event?
Which key executives will present at PRCT's 2025 investor event?
Which medical experts will provide clinical perspectives at PRCT's investor event?
How can investors access PRCT's 2025 AUA investor event?
